Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation.

Zakrzewski JL, Kochman AA, Lu SX, Terwey TH, Kim TD, Hubbard VM, Muriglan SJ, Suh D, Smith OM, Grubin J, Patel N, Chow A, Cabrera-Perez J, Radhakrishnan R, Diab A, Perales MA, Rizzuto G, Menet E, Pamer EG, Heller G, Zúñiga-Pflücker JC, Alpdogan O, van den Brink MR.

Nat Med. 2006 Sep;12(9):1039-47. Epub 2006 Aug 27.

PMID:
16936725
2.

Graft-versus-host disease after allogeneic hematopoietic stem cell transplantation induces a CD8+ T cell-mediated graft-versus-tumor effect that is independent of the recognition of alloantigenic tumor targets.

Stelljes M, Strothotte R, Pauels HG, Poremba C, Milse M, Specht C, Albring J, Bisping G, Scheffold C, Kammertoens T, Oelmann E, Silling G, Berdel WE, Kienast J.

Blood. 2004 Aug 15;104(4):1210-6. Epub 2004 Apr 15.

3.

Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.

Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR.

Biol Blood Marrow Transplant. 2003 Dec;9(12):742-52.

4.
5.

Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.

Ghosh A, Smith M, James SE, Davila ML, Velardi E, Argyropoulos KV, Gunset G, Perna F, Kreines FM, Levy ER, Lieberman S, Jay HV, Tuckett AZ, Zakrzewski JL, Tan L, Young LF, Takvorian K, Dudakov JA, Jenq RR, Hanash AM, Motta AC, Murphy GF, Liu C, Schietinger A, Sadelain M, van den Brink MR.

Nat Med. 2017 Feb;23(2):242-249. doi: 10.1038/nm.4258. Epub 2017 Jan 9.

6.

Graft-vs.-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model.

Ito M, Shizuru JA.

Biol Blood Marrow Transplant. 1999;5(6):357-68.

7.

Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.

Lu SX, Kappel LW, Charbonneau-Allard AM, Atallah R, Holland AM, Turbide C, Hubbard VM, Rotolo JA, Smith M, Suh D, King C, Rao UK, Yim N, Bautista JL, Jenq RR, Penack O, Na IK, Liu C, Murphy G, Alpdogan O, Blumberg RS, Macian F, Holmes KV, Beauchemin N, van den Brink MR.

PLoS One. 2011;6(7):e21611. doi: 10.1371/journal.pone.0021611. Epub 2011 Jul 6.

8.

Enhanced immune reconstitution by sex steroid ablation following allogeneic hemopoietic stem cell transplantation.

Goldberg GL, Alpdogan O, Muriglan SJ, Hammett MV, Milton MK, Eng JM, Hubbard VM, Kochman A, Willis LM, Greenberg AS, Tjoe KH, Sutherland JS, Chidgey A, van den Brink MR, Boyd RL.

J Immunol. 2007 Jun 1;178(11):7473-84.

9.

New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.

Waller EK, Boyer M.

Bone Marrow Transplant. 2000 May;25 Suppl 2:S20-4.

PMID:
10933181
10.

Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.

Giver CR, Montes RO, Mittelstaedt S, Li JM, Jaye DL, Lonial S, Boyer MW, Waller EK.

Biol Blood Marrow Transplant. 2003 Oct;9(10):616-32.

12.
13.
14.

Cytolytic pathways in haematopoietic stem-cell transplantation.

van den Brink MR, Burakoff SJ.

Nat Rev Immunol. 2002 Apr;2(4):273-81. Review.

PMID:
12001998
15.

Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity.

Hossain MS, Jaye DL, Pollack BP, Farris AB, Tselanyane ML, David E, Roback JD, Gewirtz AT, Waller EK.

J Immunol. 2011 Nov 15;187(10):5130-40. doi: 10.4049/jimmunol.1101334. Epub 2011 Oct 17.

16.
17.

CD4+CD25+ regulatory T cell depletion improves the graft-versus-tumor effect of donor lymphocytes after allogeneic hematopoietic stem cell transplantation.

Maury S, Lemoine FM, Hicheri Y, Rosenzwajg M, Badoual C, Cheraï M, Beaumont JL, Azar N, Dhedin N, Sirvent A, Buzyn A, Rubio MT, Vigouroux S, Montagne O, Bories D, Roudot-Thoraval F, Vernant JP, Cordonnier C, Klatzmann D, Cohen JL.

Sci Transl Med. 2010 Jul 21;2(41):41ra52. doi: 10.1126/scitranslmed.3001302.

18.

Recombinant IL-7/HGFβ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking.

Hu R, Liu Y, Song Y, Su M, Lu X, Rood D, Lai L.

Br J Haematol. 2016 Nov;175(3):505-516. doi: 10.1111/bjh.14268. Epub 2016 Jul 22.

PMID:
27447780
19.

Stromal-Derived Factor-1α and Interleukin-7 Treatment Improves Homeostatic Proliferation of Naïve CD4(+) T Cells after Allogeneic Stem Cell Transplantation.

Gauthier SD, Leboeuf D, Manuguerra-Gagné R, Gaboury L, Guimond M.

Biol Blood Marrow Transplant. 2015 Oct;21(10):1721-31. doi: 10.1016/j.bbmt.2015.06.019. Epub 2015 Jul 4.

20.

Chimerism of bone marrow mesenchymal stem/stromal cells in allogeneic hematopoietic cell transplantation: is it clinically relevant?

Miura Y, Yoshioka S, Yao H, Takaori-Kondo A, Maekawa T, Ichinohe T.

Chimerism. 2013 Jul-Sep;4(3):78-83. doi: 10.4161/chim.25609. Epub 2013 Jul 11. Review.

Supplemental Content

Support Center